NEWS HIGHLIGHTS
Published Studies Related to Phenobarbital
Current position of phenobarbital in epilepsy and its future. [2012] This article reviews the current position of phenobarbital using articles
published since 2000 and speculates on its likely future contribution to epilepsy
care. Over the last decade there have been no major double-blind randomized
placebo-controlled or comparative trials with phenobarbital.All these data
predict a healthy future for phenobarbital, particularly in helping to close the
treatment gap in low- and middle-income countries during its second century of
clinical use.
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures
and Alzheimer's disease. [2010] The objective of the study described here was to evaluate the efficacy,
tolerability, and cognitive effects of levetiracetam (LEV) in patients with
seizures and Alzheimer's disease (AD). This was a prospective, randomized,
three-arm parallel-group, case-control study of 95 patients taking LEV (n=38),
phenobarbital (PB) (n=28), and lamotrigine (LTG) (n=29)...
A randomized, triple-blind, placebo-controlled trial of prophylactic oral
phenobarbital to reduce the need for phototherapy in G6PD-deficient neonates. [2005] phototherapy among G6PD-deficient neonates... CONCLUSION: Prophylactic oral phenobarbital does not decrease the need for
Effects of phenobarbital and multiple-dose corticosteroids on developmental
outcome at age 7 years. [2003] outcomes (behavior and head circumference) at age 7 years... CONCLUSION: Antenatal phenobarbital and repetitive antenatal corticosteroid
Does perinatal phenobarbital exposure affect developmental outcome at age 2? [1999] The objective of this paper is to determine if phenobarbital exposure during
pregnancy affects developmental outcome at age 2 years. Between 1991 and 1994,
401 pregnant patients at risk for delivery prior to 34 weeks' gestation were
invited to participate; 48 mothers declined entry... It was concluded that perinatal phenobarbital therapy may
impair developmental outcome.
Clinical Trials Related to Phenobarbital
Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage [Completed]
This large randomized trial tested whether phenobarbital given to a pregnant woman about to
deliver a premature infant would prevent brain injuries in their newborns. Women with 24 to
32 week fetuses who were in preterm labor and were expected to deliver within 24 hrs were
randomized to phenobarbital or usual care. They were treated until they deliver or the fetus
reaches 33 wks gestation. Babies were followed until discharge and evaluated at 18-22 mos
corrected age for neurodevelopmental outcome.
Prophylactic Phenobarbital After Neonatal Seizures [Terminated]
The treatment of infants with medications after their seizures have stopped is very
variable. No one knows if continuing treatment with phenobarbital for up to several months
is helpful or harmful. This clinical trial is designed to help answer that question and
provide data that will help determine standard of care for these children.
Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures [Active, not recruiting]
Phenobarbital for Acute Alcohol Withdrawal [Completed]
Intravenous phenobarbital in combination with a symptom-guided standardized lorazepam-based
alcohol withdrawal protocol will be associated with decreased need for ICU admission,
continuous lorazepam infusion and will not be associated with increased adverse events.
Study of Phenobarbital Inhibition of Catamenial Epilepsy [Withdrawn]
The purpose of this study is to test the effectiveness of low-dose Phenobarbital on the
treatment of catamenial epilepsy.
We propose that since the catamenial seizures are associated with the reduction in levels of
GABA-enhancing allopregnanolone, short-term replacement with the GABAR-enhancing agent
Phenobarbital will reduce the incidence of catamenial seizures.
|